IRWDIronwood Pharmaceuticals, Inc.

1. Aug 6, 2026Raises 2026 Full-Year Financial Guidance Building on.Earnings release · press release
2. Jun 18, 2026On June 16, 2026, Ironwood Pharmaceuticals, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”)Director or officer change · Form 8-K
3. Jun 15, 2026On June 15, 2026, Ironwood Pharmaceuticals, Inc. (the “Company”) repaid in full the $200.0 million aggregate principal amount of its 1.50% convertible senior notes due 2026 (the “2026 Convertible Notes”) at their scheduled maturity.Other event · Form 8-K
4. May 21, 2026On May 19, 2026, in connection with Mr. Silver’s new role as the Company’s interim chief financial officer and principal financial officer, the Committee approved a monthly interim assignment fee of $12,250 (the “Interim CFO Assignment Fee”) for Mr. Silver.Director or officer change · Form 8-K/A
5. May 13, 2026On May 8, 2026, Gregory Martini notified Ironwood Pharmaceuticals, Inc. (the “Company”) that he is resigning from his position as Senior Vice President, Chief Financial Officer, effective May 15, 2026.Director or officer change · Form 8-K
6. May 7, 2026Ironwood Pharmaceuticals Reports Strong First.Earnings release · press release
7. Mar 11, 2026On March 10, 2026, Ironwood Pharmaceuticals, Inc. (the “Company”) notified Wells Fargo Bank, National Association, as administrative agent (in such capacity, the “Agent”), under the Credit Agreement, dated May 21, 2023, as amended by Amendment No. 1 to Credit Agreement, dated September 27, 2024 (the “Amended Credit …Other event · Form 8-K
8. Feb 25, 2026Ironwood Pharmaceuticals Reports Fourth Quarter.Earnings release · press release
9. Jan 2, 2026Maintains FY 2025 Financial Guidance and Announces FY 2026 Financial Guidance.Earnings release · press release
10. Dec 23, 2025Amendment to License Agreement with Ferring On December 18, 2025, Ironwood Pharmaceuticals, Inc. (the “Company”), solely for purposes of a limited payment guarantee, VectivBio AG, a wholly owned subsidiary of the Company (“VectivBio”), and Ferring International Center S.A. (“Ferring”), entered into that certain third …Material agreement entered · Form 8-K
11. Nov 26, 2025On November 25, 2025, the U.S. Department of Health and Human Services released the “Maximum Fair Price” (“MFP”) for LINZESS® (linaclotide), which was selected in the most recent round of government price setting as part of the Inflation Reduction Act of 2022.Other event · Form 8-K
12. Nov 10, 2025Reports Strong Third Quarter 2025 Results; Raises Full Year 2025 Financial Guidance.Earnings release · press release

Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.